Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

BACKGROUND The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide. METHODS After a four-week run-in period of treatment with budesonide (800 microg twice daily), 852 patients being treated with glucocorticoids were randomly assigned to one of four treatments given twice daily by means of a dry-powder inhaler (Turbuhaler): 100 microg of budesonide plus placebo, 100 microg of budesonide plus 12 microg of formoterol, 400 microg of budesonide plus placebo, or 400 microg of budesonide plus 12 microg of formoterol. Terbutaline was permitted as needed. Treatment continued for one year; we compared the frequency of exacerbations of asthma, symptoms, and lung function in the four groups. A severe exacerbation was defined by the need for oral glucocorticoids or a decrease in the peak flow to more than 30 percent below the base-line value on two consecutive days. RESULTS The rates of severe and mild exacerbations were reduced by 26 percent and 40 percent, respectively, when formoterol was added to the lower dose of budesonide. The higher dose of budesonide alone reduced the rates of severe and mild exacerbations by 49 percent and 37 percent, respectively. Patients treated with formoterol and the higher dose of budesonide had the greatest reductions -- 63 percent and 62 percent, respectively. Symptoms of asthma and lung function improved with both formoterol and the higher dose of budesonide, but the improvements with formoterol were greater. CONCLUSIONS In patients who have persistent symptoms of asthma despite treatment with inhaled glucocorticoids, the addition of formoterol to budesonide therapy or the use of a higher dose of budesonide may be beneficial. The addition of formoterol to budesonide therapy improves symptoms and lung function without lessening the control of asthma.

[1]  R. Roorda,et al.  One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. , 1997, American journal of respiratory and critical care medicine.

[2]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[3]  E. Israel,et al.  Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. , 1996, The New England journal of medicine.

[4]  R. Pauwels,et al.  The inhalation device influences lung deposition and bronchodilating effect of terbutaline. , 1996, American journal of respiratory and critical care medicine.

[5]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[6]  D. Cockcroft,et al.  Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. , 1996, Chest.

[7]  D. Cockcroft,et al.  Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. , 1995, American journal of respiratory and critical care medicine.

[8]  D. Cockcroft,et al.  Rapid onset of tolerance to the bronchoprotective effect of salmeterol. , 1995, Chest.

[9]  D. Yates,et al.  Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. , 1995, American journal of respiratory and critical care medicine.

[10]  M. Sears,et al.  Exacerbations of asthma without sputum eosinophilia. , 1995, Thorax.

[11]  Kwang Woo Kim,et al.  Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. , 1995, The Journal of allergy and clinical immunology.

[12]  B. Waldeck,et al.  The interaction between salmeterol and β2‐adrenoceptor agonists with higher efficacy on guinea‐pig trachea and human bronchus in vitro , 1994, British journal of pharmacology.

[13]  M. Zureik,et al.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. , 1994, The European respiratory journal.

[14]  D. Hendrick,et al.  Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. , 1994, American journal of respiratory and critical care medicine.

[15]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[16]  B. Lipworth,et al.  Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. , 1994, The American journal of medicine.

[17]  B. Lipworth,et al.  Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. , 1994, Respiratory medicine.

[18]  D. McDonald,et al.  The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. , 1994, The American journal of physiology.

[19]  M. Johnson,et al.  Comparison of the anti‐inflammatory properties of formoterol, salbutamol and salmeterol in guinea‐pig skin and lung , 1993, British journal of pharmacology.

[20]  Kevin Giblin,et al.  Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma: O'Connor BJ, Aikman SL, Barnes PJ N Engl J Med 327:1204–1208 Oct 22, 1992 , 1993 .

[21]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[22]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[23]  A. Tattersfield.  Clinical pharmacology of long-acting β-receptor agonists , 1993 .

[24]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[25]  J. Malo,et al.  Sustained improvement in asthma with long-term use of formoterol fumarate. , 1992, Annals of allergy.

[26]  P. Barnes,et al.  Tolerance to the Nonbronchodilator Effects of Inhaled β2-Agonists in Asthma , 1992 .

[27]  A. Zwinderman,et al.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. , 1992, The New England journal of medicine.

[28]  J. Palmer,et al.  A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. , 1992, The European respiratory journal.

[29]  M. Hughes,et al.  Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. , 1992, The American review of respiratory disease.

[30]  E. Naline,et al.  Formoterol and salbutamol inhibit bradykinin‐ and histamine‐induced airway microvascular leakage in guinea‐pig , 1992, British journal of pharmacology.

[31]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[32]  F. Lorgat,et al.  Evidence for in vivo generation of cytotoxic T cells. PPD-stimulated lymphocytes from tuberculous pleural effusions demonstrate enhanced cytotoxicity with accelerated kinetics of induction. , 1992, The American review of respiratory disease.

[33]  C. Löfdahl,et al.  Beta-agonists--friends or foes? , 1991, The European respiratory journal.

[34]  C. Persson,et al.  Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. , 1991, The American review of respiratory disease.

[35]  J. Malo,et al.  A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. , 1991, The American review of respiratory disease.

[36]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[37]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.